Imidazopyridines as serotonergic 5-HT.sub.3 antagonists

• US 5,434,161 A
• Filed: 11/06/1992
• Issued: 07/18/1995
• Est. Priority Date: 03/07/1991
• Status: Expired due to Fees

• Current Assignee: GD Searle LLC (Pfizer Inc.)
• Original Assignee: GD Searle LLC (Pfizer Inc.)
• Inventors: Flynn, Daniel L., Becker, Daniel P., Moormann, Alan E., Villamil, Clara I., Nosal, Roger
• Primary Examiner(s): Richter, Johann
• Assistant Examiner(s): SCALZO, CATHERINE KILBY
• Application Number:
  US07/973,126
• Time in Patent Office: 984 Days
• Field of Search: 546/121, 546/300
• US Class Current: 514/300
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The imidazopyridines compounds of the present invention are serotonergic 5-HT₃ antagonists. As such they are useful for the treatment of humans and animals wherein antagonism of 5-HT₃ receptors is beneficial. Therapy is indicated for, but not limited to, the treatment of anxiety, psychoses, depression (especially depression accompanied by anxiety), cognitive disorders, substance abuse dependence and withdrawal, gastrointestinal motility disturbancies (including esophageal reflux, dyspepsia, gastric stasis, irritable bowel syndrome), emesis caused by chemotherapeutic agents, and visceral pain. Additionally, the compounds of the present invention may find utility as enhancers of nasal absorption of bioactive compounds.

Claims

1. A compound of the formula ##STR40## the stereoisomers and pharmaceutically acceptable salts thereof, wherein R₁ is H or C_1-6 alkyl and R₂ is H or halogen;

Y represents NH or 0; and

wherein k is 1, 1 is 1, j is 0 to 4 and one of R'"'"'₃ and R'"'"'₄ is H, C_1-6 alkyl, phenyl or phenyl-C_1-3 alkyl, which phenyl moieties may be optionally substituted by C_1-6 alkyl, C_1-6 alkoxy, CF₃ or halogen and the other of R'"'"'₃ and R'"'"'₄ is H or C_1-6 alkyl.

2. The compound of claim 1 which is (endo-N-(1-Azabicyclo[3.3.1]nonan-4-yl)-6-chloroimidazo[1,2a]pyridine-8-carboxamide, dihydrochloride).

3. The compound of claim 1 which is (endo-N-(1-Azabicyclo[3.3.1]nonan-4-yl)imidazo[1,2-a]pyridine-8carboxamide, dihydrochloride).

4. A pharmaceutical composition for the treatment of anxiety, psychoses, depression, substance abuse, cognitive disorders, or gastrointestinal motility disturbances comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

5. A method of treating anxiety, psychoses, depression or gastrointestinal motility disturbances comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1.

6. A compound according to claim 1 wherein R₁ is H, R₂ is H or halo, Y is NH, j is 0 and R'"'"'₃ and R'"'"'₄ are both H.

7. A pharmaceutical composition according to claim 4 wherein R₁ is H and R₂ is H or halo, Y is NH, j is 0 and R'"'"'₃ and R'"'"'₄ are both H.

8. The method of claim 5 wherein R₁ is H, R₂ is H or halo, Y is NH, j is 0 and R'"'"'₃ and R'"'"'₄ are both H.